To examine the effect of 25-hydroxyvitamin D (25(OH)D) levels recommended by Endocrine Society guidelines (>30 ng/mL) on cognition in healthy older African-American women over 3 years. DESIGN: Randomized, double-blind, placebo-controlled clinical trial. SETTING: Bone Mineral Research Center at New York University Winthrop Hospital. PARTICIPANTS: Healthy postmenopausal African American women aged 65 and older (N=260; mean age 68.2 AE 4.9; 46% college education or higher). INTERVENTION: Half of the women were randomized to receive vitamin D (adjusted to achieve a serum level > 30 ng/mL) with calcium (diet and supplement total of 1,200 mg), and half were randomized to receive placebo with calcium (1,200 mg). MEASUREMENTS: Cognitive assessments every 6 months using the Mini-Mental State Examination (MMSE) to detect cognitive decline. Mean MMSE scores were calculated over time for both groups. Those with MMSE scores less than 21 at baseline were excluded. RESULTS: The average dose of vitamin D 3 was 3,490 AE 1,465 IU per day, and average serum 25(OH)D at 3 years was 46.8 AE 1.2 ng/mL in the active group and 20.7 AE 1.1 ng/mL in the placebo group. Serum 25(OH)D concentration was maintained at greater than 30 ng/mL in 90% of the active group. Over the 3-year period, MMSE scores increased in both groups (p < .001), although change over time was not significantly different between the groups. No adverse events associated with vitamin D were observed. CONCLUSION: There was no difference in cognition over time between older African-American women with serum concentrations of 25(OH)D of 30 ng/mL and greater than those taking placebo. There is no evidence to support vitamin D intake greater than the recommended daily allowance in this population for preventing cognitive decline. J Am Geriatr Soc 67:81-86, 2019.
D
ementia interferes with activities of daily living and comes in many forms: Alzheimer's, Lewy body, frontotemporal, and vascular dementia. Alzheimer's dementia accounts for approximately 60% to 80% of all dementias 1 and is the sixth leading cause of death overall in the United States; 2 5.5 million Americans were living with Alzheimer's dementia. 1 In 2015, the United States spent $818 billion on dementia. 3 If we discovered a connection between brain function and vitamin D, the prevention of cognitive decline by supplementation with vitamin D would be an affordable, effective, low-cost way for health practices to prevent or delay cognitive decline.
Vitamin D insufficiency is a chronic condition that is prevalent in the United States, affecting approximately 41% of the elderly population. 4, 5 Low vitamin D has been found to be associated with nursing home admission and mortality. [6] [7] [8] Vitamin D can be obtained naturally through diet, such as fortified foods and drinks, fatty fish, and fish oil, as well as supplementation and activation by the sunlight's interaction with skin. Vitamin D is known for its role in calcium homeostasis and bone health.
In addition to bone health, vitamin D has many extraskeletal roles in the body, being found in many organs, including the brain. 9 The vitamin D receptor, as well as 1-alpha hydroxylase, the enzyme that converts vitamin D to its active form (1, 25-dihydroxyvitamin D (25(OH)D)), are found in the brain, with 1-alpha hydroxylase seen in the hippocampus which is important for memory. 9 Vitamin D is neuroprotective, promoting amyloid metabolism and clearance in the brain, neuronal and synaptic growth, and neurotransmission. 10 Thus, it would seem logical that there is a link between hypovitaminosis D and dementia. 11 A previous study found that elderly adults with vitamin D deficiency (<10 ng/mL) had cognitive decline based on Mini-Mental State Examination (MMSE) results over 6 years. 11 A meta-analysis found that individuals with lower serum 25(OH)D concentrations had lower MMSE scores and were at higher risk of Alzheimer's dementia. 12 Although many clinical trials have aimed to show a relationship between vitamin D status and memory, most of these trials used overtly Caucasian populations with little ethnic variation. African Americans have lower serum 25(OH)D than their Caucasian counterparts. [13] [14] [15] One study found that 25(OH)D insufficiency was prevalent in 84% of African-Americans aged 70 to 81and 57% of Caucasians. 16 The data here was derived from a 3-year randomized clinical trial called the PODA Trial. 17, 18 We wished to determine whether maintenance of serum 25(OH)D levels above 75 nmol/L was more effective in preventing bone density loss from the total femur than placebo in older African-American women. The goal of the current study was to determine whether maintenance of serum 25(OH)D levels recommended in Endocrine Society guidelines (>30 ng/mL) is more effective than placebo in preventing cognitive decline based on MMSE scores in healthy older African-American women. By investigating the effects of vitamin D on memory, we can further investigate interventions for prevention of dementia.
METHODS

Study Design
This was a 3-year, double-blind, randomized controlled trial in healthy African-American women aged 65 and older to study the effects of high-dose vitamin D3 (serum equivalent of 30 ng/mL) on cognition using the MMSE. This group also received calcium (1,200 mg). The placebo group received calcium 1,200 mg with placebo vitamin D supplementation.
Materials and Methods
Postmenopausal African-American women aged 65 and older (N=260) were recruited for this trial. Participants were recruited in lectures by staff at churches, hospital events, and senior centers and through advertisements on flyers, postcards, and letters. Potential participants were prescreened using telephone questionnaires. They were advised to not take vitamin D-containing supplements for 4 to 6 weeks before the study. They were then screened and eventually asked to provide consent. Vitamin D levels were assessed at screening, and women with serum 25(OH)D between 8 and 26 ng/mL were included. Ambulatory postmenopausal women aged 65 and older who were selfdeclared as African American and willing to participate in the 3-year study were included. Exclusion criteria included osteoporosis of the total hip, MMSE score less than 21, moderate to severe vertebral fractures, liver disease, and kidney stones.
Once a woman qualified, she was randomized into the placebo or Vitamin D group. Of 625 women screened, 365 were excluded, and 130 were randomized to each group (see flow diagram, Figure 1 ). Participants were administered the MMSE every 6 months and had their blood drawn every year to assess vitamin D status.
Participants received vitamin D3 (2,400 IU, 3,600 IU, or 4,800 IU) or placebo, administered in 1 tablet daily, depending on study group placement. Doses depended on serum 25(OH)D levels at that visit and were adjusted to achieve and maintain a serum level of 30 ng/mL. Every 3 months, a research pharmacist the vitamin D3 dose adjusted to the nearest 30 μg. The placebo and active group doses were titrated in a similar fashion throughout the study to maintain the blind. Calcium supplements in the form of calcium carbonate were given to each group for a total of 1,200 mg per day. Calcium questionnaires were administered at each visit to assess total dietary and supplemental calcium intake.
25(OH)D was measured directly using liquid chromatography and quantitative mass spectrometry, parathyroid hormone was measured and calcium was measured using an O-cresolphthalein complex with automated equipment.
Cognitive Testing
Participants with MMSE scores less than 27 (range 30 points: orientation to time (5 points), orientation to place (5 points), registration (3 points), attention to calculation (5 points), recall (3 points), naming (2 points), repetition (1 point), comprehension (3 points), reading (1 point), writing (1 point), drawing (1 point)) were considered to have mild cognitive impairment (MCI). Scores were assessed every 6 months
Statistical Methodology
Block randomization was performed at baseline using a computer-generated (SAS Proc Plan, SAS Institute, Inc., Cary, NC) randomization list. Subjects were assigned to 1 of the 2 groups: vitamin D 3 supplementation or placebo. Any participant who was randomized and received at least 1 dose of study medication was included in the intentionto-treat (ITT) population, and primary analysis was performed according to the ITT principle. Descriptive statistics were generated and presented as meanAEstandard deviation or median (interquartile range) as appropriate for continuous data and as proportion for categorical variables. Normality of distributions of clinical variables and laboratory markers was evaluated using visual observation of histograms and the Kolmogorov-Smirnov test. Between-group differences for each continuous variable were examined using the nonparametric Wilcoxon rank-sum test for nonnormally distributed variables and the 2 independentsamples t-test for normally distributed variables. Variables were checked for outliers, and analyses were performed with and without outliers, but output remained similar, so full data were used. The Fisher exact test was used to compare categorical variables between groups.
The difference in MMSE score between treatment groups was evaluated using a repeated-measures mixed-effects linear model. An unstructured correlation structure was used to account for within-person correlation between MMSE measures over time. The model included treatment group, time, and the interaction between group and time. Missing data were assumed to have occurred at random. Treatment effect was also assessed by categorizing MMSE as a binary variable (< vs ≥27) using a repeated-measures mixed-effects logistic regression model. 19, 20 All calculations were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and R software (https://www.r-project.org). Results were considered statistically significant when P < .05.
RESULTS
Baseline Demographic Characteristics
Baseline demographic characteristics are shown in Table 1 . The average age of participants was 68.2. There was no statistically significant difference between baseline age, body mass index, calcium intake, 25-hydroxyvitamin D3 (25 (OH)D3) levels, parathyroid hormone, serum calcium level, education, and MMSE scores of each group. Baseline 25(OH)D3 overall was 21.8 AE 6.7 ng/mL (treatment group: 21.5 AE 6.5; placebo group: 22.2 AE 6.9). Fifty-eight active group participants (44.6%) and 61 placebo group participants (47.3%) had completed college. There was no statistically significant difference in education between groups. Baseline median MMSE scores were 29 in both groups. At baseline, 16 active group participants and 19 placebo group participants had MMSE scores less than 27.
Outcome Measures
Ninety-five treatment group participants and 89 placebo group participants completed 36 months. The average daily dose of vitamin D 3 given was 3,490 AE 1,465 IU, and the average serum 25(OH)D at 3 years was 46.8 AE 1.2 ng/mL in the active group and 20.7 AE 1.1 ng/mL in the placebo group. Serum 25(OH)D concentration was maintained at greater than 30 ng/mL in 90% of the active group. Over the 3-year period, MMSE scores increased in both groups In both the placebo and vitamin D3 groups, none of the dropouts were due to a gastrointestinal complaint. One dropout in the vitamin D3 group was a subject found to have primary hyperparathyroidism at the 3-month visit. Dropouts designated as "other" were due to relocation out of the state or country, general health problems, and one subject who the PI withdrew after gastric bypass surgery, because this would affect vitamin D absorption. [Color figure can be viewed at wileyonlinelibrary.com] (p < .001), although the change over time was not statistically significantly different between the groups (Figure 2) . No adverse events associated with vitamin D were observed. Adherence was 73% based on pill count. The difference in MMSE score between the 2 treatment arms was not statistically significant (group by time interaction term p = .23), although there was a statistically significantly positive effect of time (P <.001), suggesting that there was a similar increase in MMSE score in both groups regardless of treatment assignment (Figure 2 ). MMSE score was also analyzed as a binary variable. MCI was defined as a MMSE score less than 27. A mixed-effects logistic regression model revealed no difference between treatment groups over time (P = .27), the time effect was statistically significant (P <.001) (Figure 2 ).
DISCUSSION
Our double-blind, randomized, placebo-controlled trial (PODA) showed no significant difference in cognition over time according to MMSE score between older postmenopausal African-American women who took vitamin D at the level that the Endocrine Society recommend (>30 ng/mL) and those who did not. The placebo group had an average serum 25(OH)D3 level of 20.7 AE 1.1 ng/mL at 3 years, consistent with the Institute of Medicine RDA associated value (20 ng/mL). MMSE scores increased over time (p < .001), and the incidence of MCI decreased similarly in both groups during this 3-year period. To our knowledge, this is the first interventional study to attempt to show an association between vitamin D intake according to Endocrine Society guidelines and cognition in older African-American women over a long period (3 years).
Many studies that have examined vitamin D and its relationship with cognition have had conflicting results. Few interventional studies have been conducted to explore this relationship. In 2011, Dean et al. 21 looked at a young population (≥ 18) over 6 weeks to assess vitamin D on cognition and emotional behavior found improvement in working cognition over time in the placebo and vitamin D study populations and no significant difference between those groups, similar to our results. Another study 22 found no association between incidence of cognitive impairment and vitamin D treatment in women aged 65 and older receiving calcium and vitamin D. There were no significant differences in the incidence of dementia in either group (vitamin D with calcium vs placebo). A randomized trial 23 was found that visual memory improved with higher dosing of vitamin D supplementation, but verbal and other cognitive memory did not. In a 2-year longitudinal study in an elderly Chinese population, low vitamin D level was associated with low MMSE scores, with a decrease of 3 or more points considered significant. An inverse relationship was found between intake and levels of vitamin D and incidence of dementia or cognitive impairment in some longitudinal studies. 24, 25 One study 26 found that cognitive impairment may be associated with low serum 25(OH)D in AfricanAmericans.
Our study has many strengths, including its focus on African Americans, maintenance of vitamin D levels according to Endocrine Society guidelines in 90% of the active (vitamin D) population, and isolation of the effects of vitamin D by controlling calcium intake in both study groups. The longitudinal effects of vitamin D on cognition in the form of MMSE scores were measured every 6 months for 3 years, establishing a comprehensive comparison of the relationship between vitamin D level and cognition.
A major limitation of this study was that the MMSE was the only source of cognitive testing throughout. This test is best used as a screening tool and not for diagnosis. Although many clinicians use it to assess cognitive impairment because it is quick, generally easy to understand, and universal, most participants in our study were at least college educated or higher, making the MMSE less likely to detect small cognitive change over time-known as the "ceiling effect." 27 The test fails to reveal slight cognitive changes in highly educated individuals. 27 Because our population fits into this category, we used a score of less than 27 to classify those as having MCI because studies in educated, ethnically diverse 28 and Caucasian 29 populations have shown that this high cut off score increases sensitivity and specificity in detecting cognitive changes in highly educated individuals. Although false positives would be more likely with this cut off score, using it would increase detection of individuals with early-onset dementia and MCI that would otherwise go undiscovered. Some limitations of the MMSE were that there were no quality checks of those administering the test, and a learning effect could have been introduced as participants advanced in the study. Nevertheless, the MMSE is a standard test, and although there were no quality checks, the test is objective and can be used universally.
Overall, this study should not be generalized to the general population. The study population in this trial was relatively healthy, with generally higher vitamin D levels than usual in African Americans. Therefore, our results should not be generalized to those who are unhealthy or vitamin D deficient. Because our focus was on AfricanAmerican women, our results may not generalize to individuals of other races or men. The drop-out rate was another limitation.
In conclusion, we found that there was no benefit in maintaining serum 25(OH)D at greater than 30 ng/mL (Endocrine Society guidelines) in terms of cognition. Cognition improved over time in our older African-American, female population, with no difference between women receiving vitamin D and those receiving placebo. The study population was relatively healthy, and vitamin D levels were already higher than the Institute of Medicine's recommendations. Women with baseline dementia were excluded. It is unclear whether pattern recognition and memorization from repeated MMSE testing from previous visits played a part in recall of MMSE exercises. Also, because only the MMSE was used in a well-educated population, this may not have been enough to detect subtle changes in memory. Because of the standardization of the examination, the difference between test givers should not have played a role. More interventional studies that explore the relationship between vitamin D status and cognition need to be conducted in ethnically diverse populations to compare results universally. Future studies with larger participant populations and broader cognitive testing will be useful.
